DCIS Recurrence Rate Low in Young Women

I tend to disagree with these findings from above, based on more current research studies, since this also seems a bit outdated from 2008. Many young women tend to have more aggressive and sometimes multi-focal forms of DCIS with grade 3 tumors, more suggestive of higher rates of recurrence as well. Read more below:

Younger women had nearly double the risk for recurrence after surgery for DCIS.

Researchers in Canada have found that women aged 44 and younger were almost twice as likely to have cancer recurrence following breast conservation surgery and radiation therapy for ductal carcinoma in situ compared with women aged 45 to 50.

Results of a retrospective study showed that the rate of recurrence was 20% in women aged 40 and younger (n=70) compared with 19% for women 40 to 44 (n=195) and 12% for women 45 to 50 (n=356).

The HR for recurrence in women younger than 40 was 1.83 (95% CI, 1.00-3.36); it was 1.64 for those aged 40 to 44 (95% CI, 1.06-2.53), even after adjusting for the use of boost radiation, nuclear grade-3 and year of diagnosis.

This is preliminary data and further work is needed to better understand why younger women have higher recurrence rates, as well as to determine the optimal treatment for young women with DCIS, said Iwa Kong, MD, a breast radiation oncology research fellow at the Sunnybrook Health Sciences Center, Toronto. She presented the results at the 2009 Breast Cancer Symposium in San Francisco.

In a press release, she added that these results do not suggest that all younger women should undergo more aggressive surgery.

Researchers evaluated the rate of recurrence among 624 women in Ontario aged 50 or younger. The women were diagnosed with ductal carcinoma in situ from 1994 to 2003. All underwent standard breast conservation surgery followed by radiation. Median follow-up was 7.8 years.

Kong said there were 96 recurrences of both in situ and invasive breast cancers in the cohort (15.4%). Five-year OS was excellent and not different between groups at 97% to 99%.

However, younger women had lower actuarial recurrence-free survival at five and 10 years. Five-year recurrence-free survival was 84% for women younger than 44 compared with 90% for those 45 to 50 by Jason Harris

 http://www.hemonctoday.com/article.aspx?rid=44574